Axamon, solution ampoules 5mg/ml 1ml 10pcs

Composition

>1 ml for the drug contains: Active ingredient: ipidacrine hydrochloride monohydrate – in terms of anhydrous) – 5 mg; excipients: 0.1 M hydrochloric acid solution-up to pH 3.00; water for injection – up to 1 ml

Pharmacological action

Axamon® is a reversible cholinesterase inhibitor that directly stimulates impulse conduction in the neuromuscular synapse and in the central nervous system (CNS) due to the blockade of the potassium channels of the membrane. Increases the effect on smooth muscles of not only acetylcholine, but also epinephrine, serotonin, histamine and oxytocin.

Axamon® has the following pharmacological effects:

– improves and stimulate impulse conduction in the nervous system and neuromuscular transmission;

– improves the conductivity of the peripheral nervous system, impaired due to injury, inflammation, effects of local anesthetics, some antibiotics, potassium chloride, etc. ;

– increases the contractility of smooth muscle organs under the influence of agonists acetylcholine, adrenaline, serotonin, histamine and oxytocin receptors, with the exception of potassium chloride;

– improves memory, progradient inhibits the development of dementia.

It has no teratogenic, embryotoxic, mutagenic, carcinogenic or immunotoxic effects. It does not affect the endocrine system.

Indications

• diseases of the peripheral nervous system: mono-and polyneuropathy, polyradiculopathies, myasthenia gravis and myasthenic syndrome of various etiologies;
• diseases of the central nervous system: bulbar paralysis and paresis;
• recovery period of organic lesions of the central nervous system, accompanied by motor disorders;
• intestinal atony.

Contraindications

• Hypersensitivity to any of the components of the drug,
• epilepsy,
• extrapyramidal disorders with hyperkinesis,
• angina pectoris,
• severe bradycardia,
• bronchial asthma,
• mechanical obstruction of the intestine or urinary tract,
• vestibular disorders,
• peptic ulcer of the stomach or duodenum in the acute stage,
• children under 18 years of age (no systematic data on the use).

Use caution when: gastric and duodenal ulcers, thyrotoxicosis, diseases of the cardiovascular system, obstructive diseases of the respiratory system in the anamnesis or acute respiratory diseases. If you have one of these diseases, be sure to consult your doctor before taking the drug.

Side effects

the incidence of adverse reactions that may arise during the use of the drug, as shown in the following classification: very often (>1/10 appointments), common (1/10-1/100 of appointments), rare (1/100-1/1000 appointments), rare (1/1000-1/10000 appointments), very rare (mental Disorders: infrequently – drowsiness. Nervous system disorders: infrequent – dizziness, headache, convulsions;  unknown frequency – tremor. Visual disturbances: of unknown frequency – miosis. Cardiac disorders: frequent – palpitations, bradycardia; unknown frequency-pain behind the sternum. Respiratory, thoracic, and mediastinal disorders: infrequent – increased bronchial secretions. Gastrointestinal disorders: frequent-salivation, nausea; infrequent-vomiting; rare-diarrhea, epigastric pain. Liver and biliary tract disorders: jaundice of unknown frequency. Skin and subcutaneous tissue disorders: infrequent-itching, rash. General disorders and disorders at the injection site: frequent-increased sweating; infrequent-general weakness; unknown frequency-hypothermia. Salivation and bradycardia can be reduced with m-holinoblockers (atropine, cyclodol, metacin, etc. ). If itching or rash occurs, stop taking the drug. In other cases, reduce the dose or stop taking the drug for a short time (for 1-2 days). If any of the side effects listed in the instructions get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

Axamon ® enhances the sedative effect in combination with drugs that depress the central nervous system. The effect and side effects are enhanced when combined with other cholinesterase inhibitors and m-cholinomimetic agents. In patients with myasthenia gravis, the risk of developing a cholinergic crisis increases if Axamon® is used simultaneously with other cholinergic agents. The risk of developing bradycardia increases if beta-blockers were used before starting treatment with Axamon®. Weakens the inhibitory effect on the neuromuscular transmission and conduction of excitation along the peripheral nerves of local anesthetics, aminoglycosides, and potassium chloride. Axamon® can be used in combination with nootropic drugs. Alcohol increases the side effects of the drug.

How to take, course of use and dosage

Subcutaneously or intramuscularly. The dose and duration of treatment are determined individually, depending on the severity of the disease. Diseases of the peripheral nervous system:  * mono-and polyneuropathies of various origins, polyradiculopathies: subcutaneously or intramuscularly 5-15 mg 1-2 times a day, a course of 10-15 days (in severe cases-up to 30 days); then treatment is continued with the tablet form of the drug; * myasthenia gravis and myasthenic syndrome: subcutaneously or intramuscularly 15-30 mg 1-3 times a day with further transition to tablet form. The general course of treatment is 1-2 months. If necessary, the treatment can be repeated several times with a break between courses of 1-2 months.

CNS diseases

* bulbar paralysis and paresis: subcutaneously or intramuscularly 5-15 mg 1-2 times a day, a course of 10-15 days; then, if possible, switch to the tablet form; • recovery period of organic CNS lesions accompanied by motor disorders: intramuscularly 10-15 mg 1-2 times a day, a course of up to 15 days; then, if possible, switch to the tablet form.

Treatment and prevention of intestinal atony: the initial dose is 10-15 mg 1-2 times a day for 1-2 weeks.

Overdose

Symptoms: decreased appetite, bronchospasm, lacrimation, increased sweating, pupil constriction, nystagmus, increased gastrointestinal motility, spontaneous defecation and urination, vomiting, jaundice, bradycardia, impaired intracardiac conduction, arrhythmias, decreased blood pressure, anxiety, anxiety, agitation, fear, ataxia, convulsions, coma, speech disorders, drowsiness and general weakness. Treatment: use of m-holinoblokatorov (atropine, cyclodol, metacin, etc. ), symptomatic therapy.

Special instructions

During treatment, you should refrain from driving a car, other vehicles and mechanisms, as well as from engaging in potentially dangerous activities that require increased concentration of attention and speed of psychomotor reactions.

Storage conditions

In a dark place at a temperature not exceeding 25 °C. Keep out of reach of children.

Shelf

life is 2 years.

Active ingredient

Ipidacrine

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection

Description

For adults as directed by your doctor

Indications

Polyneuropathy, Stroke Effects, Alzheimer ‘s Disease